Hepatic Encephalopathy Support Protocol
Primary Stack
Core supplements with strongest evidenceEnhances ammonia detoxification and provides neuroprotection; L-ornithine L-aspartate (LOLA) is the standard form studied for HE
Compete with aromatic amino acids for brain uptake; may improve mental status and protein tolerance
Supporting Stack
Additional supplements for enhanced resultsCofactor for urea cycle enzymes; deficiency common in cirrhosis; supplementation may reduce ammonia levels
Supporting Studies (1)
Reduce ammonia-producing gut bacteria; decrease intestinal ammonia absorption and systemic inflammation
Neuroprotective antioxidant; may reduce oxidative stress and inflammation in hepatic encephalopathy
Supporting Studies (1)
Deficiency extremely common in liver disease; associated with worse outcomes; supplementation may support brain function
Supporting Studies (1)
Anti-inflammatory effects may reduce systemic inflammation contributing to encephalopathy
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Hepatic encephalopathy (HE) is a brain dysfunction caused by liver disease. When the liver can't properly detoxify blood, toxins—especially ammonia—build up and affect brain function. Symptoms range from subtle cognitive changes (minimal HE) to confusion, personality changes, sleep disturbances, and in severe cases, coma. HE typically occurs in people with cirrhosis, especially after a precipitating event like infection, GI bleeding, constipation, or medication changes.
CRITICAL: Hepatic encephalopathy requires medical management. Standard treatment includes lactulose and/or rifaximin to reduce ammonia. This protocol is ADJUNCTIVE to standard therapy, not a replacement. Acute HE requires immediate medical attention.
Expected timeline: LOLA effects: within days to weeks for acute episodes. Zinc: 2-4 weeks to correct deficiency. Probiotics: 2-4 weeks for gut effects. These supplements support standard HE therapy and ongoing liver disease management.
Clinical Perspective
Hepatic encephalopathy represents a spectrum of neuropsychiatric manifestations in patients with liver dysfunction. West Haven criteria grade severity (0-4). Pathophysiology: hyperammonemia is central, but systemic inflammation, oxidative stress, and neurotransmitter alterations (glutamate/GABA imbalance, altered dopaminergic/serotonergic function) also contribute. Precipitants include infection, GI bleeding, constipation, electrolyte disturbances, medications (sedatives, diuretics), dehydration. Standard treatment: lactulose (target 2-3 soft stools/day) and/or rifaximin (550mg BID).
CRITICAL: HE requires standard medical management (lactulose, rifaximin). Identify and treat precipitating factors. Acute overt HE requires hospitalization. Supplements are adjunctive to standard therapy. Monitor for medication interactions in cirrhosis (altered drug metabolism).
Biomarker targets: Ammonia levels (though poorly correlate with severity), liver function tests, coagulation (INR/PT), neuropsychological testing (PHES, CFF for minimal HE), quality of life measures, stool frequency (target 2-3/day on lactulose), nutritional status, zinc levels.
Protocol notes: Lactulose is cornerstone—titrate to 2-3 soft stools/day; works by acidifying colon (traps ammonia as NH4+), reduces transit time, alters gut flora. Rifaximin added for recurrent HE (reduces recurrence by 50%). Identify precipitants: infection (SBP, UTI, pneumonia), GI bleeding, constipation, medications (sedatives, NSAIDs, excessive diuretics), electrolyte disturbances (hypokalemia, hyponatremia), dehydration, dietary protein excess (rare). Adequate protein intake is important—protein restriction is no longer recommended (leads to sarcopenia). Small frequent meals. Avoid constipation. Sleep hygiene (circadian disruption in HE). Avoid sedatives. Driving restrictions for overt HE. Liver transplant evaluation if recurrent HE despite treatment. Minimal HE affects quality of life and driving ability—screen with psychometric tests.